• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

India’s Pharma Market to "Skyrocket to $55 Billion by 2020", Says Report

Article

January 28, 2016.

The pharma market in India, valued at $20 billion in 2015, is set to soar to $55 billion by 2020, according to GlobalData.

India’s generics market will see sales grow by nearly 84% to $26.1 billion in 2016, says the GlobalData report.

Indian companies are "now exporting to countries like Brazil, Mexico, South Africa, Russia and Japan, and, according to India’s Ministry of Commerce and Industry, the nation’s pharmaceutical export segment has more than doubled from $7.8 billion in 2008 to $16.5 billion in 2014," said analyst Adam Dion, MSc.

The country's biosimilars market is also expected to increase to $40 billion globally by 2020.

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – India

Related Videos
Related Content
Say Hello to Flexible: Reimagining the Patient Journey

Say Hello to Flexible: Reimagining the Patient Journey

April 15th 2024
Article

Through embracing connected and tech-enabled services and devices, new avenues and opportunities exist for greater clinical trial flexibility in drug research.

Stock.adobe.com

ArisGlobal Announces Second Life Sciences Generative AI Council Session

April 11th 2024
Article

The meeting is scheduled for May in Switzerland.

Image credit: ArtemisDiana | stock.adobe.com

Precision Medicine: Investments and Outcomes Expected

March 18th 2024
Article

Precision medicine is now seen as a healthcare approach for both the present and the future, particularly with the explosion of personalized care delivery.

Dan Milczarski, Executive Vice President of Process and Technology, CQfluency.

All in on AI is Not the Solution in Life Sciences and Health Care

March 13th 2024
Article

Although life science organizations are not immune to the benefits of artificial intelligence, it’s important to integrate it with caution because there is no “one-size fits all” approach.

Andrew Anderson

Normalizing Data with AI: Q&A with Andrew Anderson, VP of Innovation and Informatics Strategy at ACD/Labs

March 8th 2024
Article

Anderson discusses how AI can be used to take data collected by different processes and bring it into a usable format.

Deborah L. Ancona, Seley Distinguished Professor of Management, Professor of Organization Studies, founder of the MIT Leadership Center at the MIT Sloan School of Management.

With Generative AI, Layoffs Increasing Complexity for C-Suites in 2024, What Playbook Should Executives Deploy for the Next Three Quarters?

February 27th 2024
Article

A Harvard Business School Healthcare Alumni Association (HBSHAA) Q&A with Professor Deborah Ancona, founder of the MIT Leadership Center.